With Cancer Drug in Trials, Mersana Therapeutics, Inc. Gets $6 Million

Published: Apr 22, 2011

Mass High Tech -- Mersana Therapeutics Inc has raised $6 million of a planned $10 million debt round with private investors, the company reported in a regulatory filing on Thursday. The Cambridge company develops medicines using a proprietary, biodegradable polymer it calls Fleximer. Last month, Mersana announced it had moved a cancer treatment, XMT-1001, forward in clinical trials, beginning a Phase 1b extension study of its treatment for second-line gastric cancer and second- and third-line non-small cell lung cancer.

Back to news